Neok Bio announced FDA clearance of an investigational new drug application for NEOK‑001, a bispecific antibody–drug conjugate, clearing the way for a phase I trial in solid tumors. The company said dosing is expected to start in the coming months and initial clinical data may follow next year. The IND positions Neok to test its bispecific ADC modality in a solid‑tumor setting and adds to the growing wave of ADC and bispecific clinical starts. Sponsors and investors will watch safety and early signal-of-activity data closely given the platform’s translational and commercial implications.